| Followers | 3 |
| Posts | 222 |
| Boards Moderated | 0 |
| Alias Born | 02/23/2024 |
Wednesday, March 13, 2024 4:08:53 AM
Indeed, let's be honest. A drug 30 years in the making. Trial and error, more enemies than friends, lots of money...
It really could be 1 of the most sold drugs all over the world. They are present in the USA, in the EU and in the UAE allready ...
I mean, even with the dilution of shares, up until 300 million shares... It is not a lot.. It is a standard amount in biotech. So, I can imagine some tricks to scare investors out of their positions. This could become 1 of the most epic returns on investment, in a short period of time, ever seen.
Market cap at 5 million, while the drug will generate in the billions. As long as the results are not out, we can expect some more trickery in my opinion. It happened multiple times before, especially via Seeking Alpha articles (in other stocks) -> also in the other way, positive news, unofficial, to keep the faith, while bad results came out later... So, if I see an article, unofficial, stating negative news... I expect positive news.
It really could be 1 of the most sold drugs all over the world. They are present in the USA, in the EU and in the UAE allready ...
I mean, even with the dilution of shares, up until 300 million shares... It is not a lot.. It is a standard amount in biotech. So, I can imagine some tricks to scare investors out of their positions. This could become 1 of the most epic returns on investment, in a short period of time, ever seen.
Market cap at 5 million, while the drug will generate in the billions. As long as the results are not out, we can expect some more trickery in my opinion. It happened multiple times before, especially via Seeking Alpha articles (in other stocks) -> also in the other way, positive news, unofficial, to keep the faith, while bad results came out later... So, if I see an article, unofficial, stating negative news... I expect positive news.
Recent JAGX News
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/29/2026 09:23:41 PM
- Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders • ACCESS Newswire • 05/28/2026 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/27/2026 01:10:06 PM
- Jaguar Health Compliant with Nasdaq Bid Price Rule • ACCESS Newswire • 05/27/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 09:22:44 PM
- Jaguar Health Reports First Quarter 2026 Financials • ACCESS Newswire • 05/20/2026 08:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2026 08:36:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/20/2026 08:06:56 PM
- Jaguar Health to Hold Investor Webcast May 26 Regarding Q1 2026 Financials & Corporate Updates; Jaguar CEO Lisa Conte Presenting May 28 at Lytham Partners Spring 2026 Investor Conference • ACCESS Newswire • 05/20/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/19/2026 09:07:21 PM
- Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA) for Liquid Oral Crofelemer • ACCESS Newswire • 05/19/2026 01:00:00 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/18/2026 07:06:14 PM
- Jaguar Health Regains Compliance with Nasdaq's Publicly Held Shares Requirement and Receives Additional Extension, Until May 18, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule • ACCESS Newswire • 05/08/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 06:59:08 PM
- Jaguar Health Announces Preliminary Discussion with FDA to Evaluate Breakthrough Therapy Designation for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID) • ACCESS Newswire • 05/06/2026 01:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2026 12:00:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/04/2026 09:09:41 PM
- Jaguar Health Expands Neonorm Franchise with Introduction of Neonorm Dog for Companion Animal Gut Health • ACCESS Newswire • 05/04/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/04/2026 12:00:18 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/30/2026 01:57:16 PM
- Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia-CA1) for Treatment of Chemotherapy-Induced Diarrhea in Dogs • ACCESS Newswire • 04/29/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/27/2026 01:10:06 PM
- Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule; Company Announces Reverse Stock Split • ACCESS Newswire • 04/27/2026 01:00:00 PM
- Jaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN) • ACCESS Newswire • 04/24/2026 12:30:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/21/2026 12:22:02 PM
